PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hhmipaAbout Author manuscriptsSubmit a manuscriptHHMI Howard Hughes Medical Institute; Author Manuscript; Accepted for publication in peer reviewed journal
 
Nat Immunol. Author manuscript; available in PMC Apr 12, 2013.
Published in final edited form as:
Published online Mar 27, 2011. doi:  10.1038/ni.2016
PMCID: PMC3623929
HHMIMSID: HHMIMS449092
Stim1, PKCδ and RasGRP proteins set a threshold for pro-apoptotic Erk signaling during B cell development
Andre Limnander,1 Philippe Depeille,2 Tanya S. Freedman,1 Jen Liou,3 Michael Leitges,4,5 Tomohiro Kurosaki,6,7 Jeroen P. Roose,2 and Arthur Weiss1
1Department of Medicine, Howard Hughes Medical Institute, Rosalind Russell Medical Research Center for Arthritis
2Department of Anatomy, University of California at San Francisco, 513 Parnassus Ave, San Francisco, CA 94143
3Department of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas 75390-9040
4Division of Nephrology, Department of Medicine, Hannover Medical School, Hannover, Germany
5The Biotechnology Centre of Oslo, University of Oslo, Norway
6Laboratory for Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan
7Laboratory for Lymphocyte Differentiation, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, Japan
Correspondence should be addressed to: a.w. (aweiss/at/medicine.ucsf.edu)
Clonal deletion of autoreactive B cells is crucial to prevent autoimmunity, but the signaling mechanisms that regulate this checkpoint remain undefined. Here we characterized a previously unrecognized Ca2+-driven Erk activation pathway, which was pro-apoptotic and biochemically distinct from DAG-induced Erk activation. This pathway required PKCδ and RasGRP proteins and depended on Stim1 concentrations, which control the magnitude of Ca2+ entry. Developmental regulation of these proteins was associated with selective activation of the pathway in B cells prone to negative selection. This checkpoint was impaired in PKCδ-deficient mice, which developed B cell autoimmunity. Conversely, Stim1 overexpression conferred a competitive disadvantage to developing B cells. These findings establish Ca2+-dependent Erk signaling as a critical pro-apoptotic pathway that mediates B cell negative selection.
Early B cell development in the bone marrow is characterized by genetic rearrangements of the immunoglobulin locus that lead to the production of a unique B cell receptor (BCR) on the surface of each B cell. This process generates an exceptionally diverse repertoire of B cells for the recognition of potential foreign invaders. However, a sizeable portion of the initial repertoire has the ability to recognize self and these cells must be modified, silenced or eliminated to prevent later autoimmunity15. Immature bone marrow B cells initially express the BCR as membrane-bound IgM, establishing the first opportunity for the cell to recognize antigen. Antigen engagement at this stage results in upregulation of the recombination machinery and receptor editing, one way by which autoreactivity can be avoided while rescuing the cell6. However, as cells progress through development and continue increasing the surface abundance of IgM and IgD, they lose the ability to edit the receptor and instead become increasingly sensitive to antigen-induced apoptosis7. These transitional bone marrow cells thus undergo apoptosis upon antigen encounter, a second checkpoint to avoid the development of later autoimmunity. Cells that survive past this stage then leave the bone marrow and migrate to the spleen, where they undergo additional selection checkpoints before completing maturation. Once B cells reach a mature stage, they become resistant to antigen-induced apoptosis and instead mount vigorous proliferative responses to antigen. Therefore, developmental changes during B cell maturation alter signaling responses to antigen in ways that lead to different functional outcomes. The molecular mechanisms by which antigen encounter leads to editing, apoptosis or proliferation at different stages of B cell development are not well understood.
Compared to mature B cells, developing B cells display decreased diacylglycerol (DAG) production and increased amplitude and duration of Ca2+ entry in response to antigen, particularly at low antigen concentrations811. Ca2+ is essential for both receptor editing and antigen-induced apoptosis7, implying that increased amplitude of Ca2+ entry in developing B cells likely contributes to their increased sensitivity to antigen-induced apoptosis. The mechanism that drives Ca2+ into a lymphocyte is initiated by depletion of intracellular stores: antigen receptor crosslinking leads to activation of phospholipase C-γ (PLC-γ), which converts PtdIns(4,5)P2 into Ins(1,3,4)P3 and DAG; IP3 then binds IP3 receptors on the endoplasmic reticulum (ER) membranes, leading to depletion of Ca2+ from the ER stores. This triggers an initial increase in cytoplasmic Ca2+ concentration, which is followed by opening of the Ca2+ release activated Ca2+ (CRAC) channels (or other SOC channels, such as TRP channels, depending on the cell type) at the plasma membrane. Extracellular Ca2+ then flows into the cell following a ten-thousand-fold gradient and further prolongs the increases in intracellular Ca2+ concentration, a process is known as store-operated Ca2+ entry (SOCE)12. The mechanism that couples ER store release to opening of the plasma membrane channels has only recently been defined, in part due to the identification of Stim1 as the long-sought ER Ca2+ sensor1315. Stim1 is a transmembrane ER protein that contains a Ca2+-binding EF hand localized in the lumen of the ER. Under resting conditions, Stim1 is Ca2+-bound and evenly distributed through the ER membrane. Upon release of the ER Ca2+ stores Stim1 becomes Ca2+ unbound, clusters and moves toward the plasma membrane where it interacts with the channels1620, causing them to open and triggering entry of extracellular Ca2+. Stim1 is thus essential for SOCE, but the extent to which Stim1 protein abundance influences the potential magnitude of Ca2+ responses has not been explored.
Here we used Stim1 to establish a system for sensitization of B cells to antigen receptor-induced apoptosis. Using this system we identified and characterized a previously unrecognized Ca2+-driven pathway involved in Erk activation. We demonstrated that Stim1 overexpression in a B cell line augmented the amplitude and duration of Ca2+ entry and enhanced antigen receptor-induced apoptosis. By mass spectrometry we identified a Ca2+-dependent pathway to Erk with biochemical requirements distinct from those for DAG-mediated Erk activation. Activation of this Ca2+-dependent pathway required RasGrp and PKCδ activity, and its disruption rescued the cells from antigen receptor-induced apoptosis. Furthermore, we identified S332 on human RasGRP1 as a potential phosphorylation site that is a likely target for protein kinase Cδ and was essential for activation of this Ca2+-Erk pathway. Stim1, PKCδ and RasGRP proteins were all differentially expressed in primary bone marrow B cells prone to negative selection and as a result, this pathway was selectively activated in these B cell subsets. PKCδ-deficient developing B cells failed to activate this pathway, which correlates with development of self-reactive B cells and autoimmunity in these mice21, 22. In contrast, developing B cells overexpressing Stim1 displayed increased negative selection at the bone marrow transitional stage, and this effect required PKCδ. Our findings demonstrate that DAG and Ca2+ can direct Erk signaling towards different functional outcomes, thus outlining a molecular mechanism by which developmental regulation of Ca2+- and DAG-dependent Erk pathways can determine B cell fate.
Stim1 increases SOCE and apoptosis in DT40 B cells
Recent work has described an important role for Stim1 in store-operated Ca2+ entry (SOCE)1315. We hypothesized that Stim1 might act as the limiting factor to control the rate of CRAC channel opening and thus control induction of apoptosis. Indeed, DT40 B cells stably over-expressing eYFP-Stim1 (Supplementary Fig. 1) displayed increased amplitude and duration of SOCE relative to wild-type DT40 cells in response to either BCR stimulation, thapsigargin or cyclopiazonic acid (CPA) (Fig. 1a, Supplementary Fig. 2a). Thapsigargin and CPA trigger SOCE by inhibiting the SERCA pumps in the ER, thereby inducing passive release of Ca2+ from the ER stores while bypassing proximal BCR signaling. Consistent with a role for Ca2+ in antigen-induced apoptosis8, 10, Stim1 overexpression sensitized DT40 cells to both BCR- and thapsigargin-induced apoptosis (Fig. 1b). Furthermore, chelating extracellular Ca2+ with EGTA during either stimulation regimen rescued the cells from apoptosis. Therefore, Ca2+-dependent pro-apoptotic signals are enhanced in Stim1-overexpressing DT40 cells.
Figure 1
Figure 1
Sensitization of B cells to antigen-induced apoptosis correlates with Ca2+- dependent Erk activation
Increased SOCE leads to Ca2+-dependent Erk activation
We examined the phosphotyrosine profile of Stim1-overexpressing DT40 B cells following thapsigargin stimulation for 2 and 5 minutes and observed robust and sustained tyrosine phosphorylation of a ~42 kDa band, which was only modestly detectable in thapsigargin-stimulated wild-type DT40 cells (Fig. 1c). Immunoprecipitation of this protein with a phosphotyrosine antibody (Fig. 1d), followed by mass spectrometry identified this band as Erk2. To confirm the identity of this protein, DT40 cells or Stim1-overexpressing DT40 cells were stimulated over time with thapsigargin or CPA in the presence or absence of extracellular Ca2+, and the phospho-Erk (pErk) responses were analyzed by flow cytometry. While Ca2+-dependent Erk activation was modest and short-lived in wild-type DT40, it was robust and sustained in Stim1-overexpressing DT40 cells (Fig. 1e,f, Supplementary Fig. 2b). Chelation of extracellular Ca2+ by EGTA effectively abrogated the thapsigargin- or CPA-induced pErk response, demonstrating that the robust Erk activation observed in the Stim1-overexpressing DT40 cells is due to the increased SOCE in these cells.
Antigen-induced Erk activation in lymphocytes is thought to be DAG-dependent and mostly Ca2+-independent2327. However, we hypothesized that a parallel, Ca2+-driven pathway to Erk may become relevant in B cells when the SOCE is more intense relative to the limited DAG signals10, and longer lasting than the DAG signal. Stim1-overexpressing DT40 cells had increased and prolonged pErk production in response to BCR stimulation with respect to wild-type DT40 cells, and the increased amplitude and duration of the response depended on extracellular Ca2+ (Fig. 2a,b). To determine whether this pathway to Erk is predominantly triggered by Ca2+ and less by DAG, we utilized diacylglycerol kinase ζ (DGKζ), which converts DAG to phosphatidic acid, thereby inhibiting DAG-dependent responses28. We transfected Stim1-overexpressing DT40 cells with DGKζ and CD16 as a surrogate cell surface marker for transfected cells. The cells were then stimulated with either thapsigargin or a dose of anti-BCR that elicits an equivalent pErk response in the untransfected population (Fig. 2c,d). DGKζ expression did not inhibit thapsigargin-induced Ca2+-dependent pErk (Fig. 2c,d). In contrast, BCR crosslinking, which triggers DAG production as well as SOCE, elicited a pErk response that was partially inhibited by DGKζ. Addition of EGTA at the time of BCR crosslinking led to further inhibition of the pErk response, demonstrating that simultaneous inhibition of Ca2+ and DAG can almost entirely ablate Erk activation in these cells. Thus, BCR stimulation can activate Erk via distinct DAG- or Ca2+-dependent pathways and the kinetics of Ca2+ entry and DAG production affect the relative contribution of these pathways to the overall response.
Figure 2
Figure 2
BCR stimulation activates Erk via two distinct pathways primarily activated by either Ca2+ or DAG
Ca2+-Erk signaling in bone marrow developing B cells
We next investigated whether the activation of this Ca2+-Erk pathway that we observed in our DT40 B cell model with Stim1 expression also occurs in primary B cells. Bone marrow cells from wild-type C57BL/6 mice were stimulated with thapsigargin over time, fixed, permeabilized, stained for pErk in combination with cell surface markers and analyzed by flow cytometry. Only immature and transitional B cells, but not earlier precursors or mature recirculating B cells, displayed robust Ca2+-dependent Erk activation (Fig. 3). Ca2+-dependent Erk activation was less robust in splenic transitional subsets than in bone marrow immature and transitional cells (data not shown), suggesting that this pathway is more relevant in the bone marrow. Thus, B cells are altered developmentally to allow the activation of this pathway specifically in bone marrow B cell populations known to be highly sensitive to apoptosis, where an important checkpoint for the deletion of self-reactive B cells occurs.
Figure 3
Figure 3
Ca2+-dependent Erk activation occurs selectively at stages of negative selection in primary bone marrow B cells
Loss of Stim1-overexpressing developing B cells
We next hypothesized that, similar to the effect observed in DT40 cells, increasing Stim1 in bone marrow hematopoietic progenitors might increase SOCE, enhance Ca2+-dependent Erk signaling and sensitize developing B cells to negative selection. To test this hypothesis, we infected bone marrow hematopoietic stem cells expressing different congenic markers with retroviruses carrying eYFP or eYFP-Stim1. These cells were used in competitive repopulation experiments and the survival of eYFP-Stim1+ B cells was traced throughout development relative to eYFP+ B cells. eYFP-Stim1+ cells were markedly outcompeted by eYFP+ cells (Fig. 4), resulting in very low numbers of eYFP-Stim1+ peripheral B cells. The greatest loss of Stim1+ B cells occurred in bone marrow stages that correlate with the developmental onset of Ca2+-dependent Erk activation. Thus, increasing Stim1 expression confers a competitive disadvantage to developing B cells at the same stages that are most sensitive to thapsigargin-induced activation of Erk in unmanipulated bone marrow B lineage cells. To test whether this out-competition is due to increased negative selection, we examined the effect of Stim1 on developing MD4 transgenic B cells, which express a transgenic BCR that recognizes hen egg lysozyme (IgHEL). Hematopoietic stem cells (HSCs) from MD4 mice were infected with eYFP-Stim1 and injected into lethally irradiated wild-type recipient mice. The survival of eYFP-Stim1-transduced MD4 B cells relative to non-transduced MD4 B cells was traced throughout development. In the absence of antigen, MD4 B cells overexpressing eYFP-Stim1 competed efficiently with non-transduced cells during bone marrow development (Supplementary Fig. 3). In fact, occasionally mice demonstrated an expansion of eYFP-Stim1+ cells relative to non-transduced cells, an effect that is opposite to what was observed in mice with an unrestricted B cell repertoire. Therefore, restricting the BCR repertoire to IgHEL in the absence of antigen (HEL) is sufficient to rescue the competitive disadvantage of Stim1-overexpressing B cells. These findings demonstrate that Stim1 overexpression sensitizes developing B cells to negative selection.
Figure 4
Figure 4
Stim1 overexpression confers a competitive disadvantage to developing B cells
RasGRP-dependent Ca2+-Erk signaling is pro-apoptotic
We next investigated the mechanism by which SOCE activates Erk to determine if a causal relationship between this pathway and apoptosis exists. Calcium increases are not generally thought to modulate the MAPK pathways leading to Erk activation. RasGrp and SOS are Ras guanine nucleotide exchange factors (RasGEFs) involved in RasGTP production upstream of Erk activation in lymphocytes25, 2933. RasGrp proteins contain both DAG-binding C1 domains and Ca2+-binding EF hands, and they have been proposed to mediate pro-apoptotic signals in B cells34, 35. Although DAG is important for RasGrp activity, we hypothesized that, under conditions of high SOCE, Ca2+ could potentially trigger activation of RasGrp as well, leading to Erk activation. We first transiently transfected Rasgrp1−/−Rasgrp3−/− or Sos1−/−Sos2−/− DT40 cells32 with eYFP-Stim1 and examined the ability of these cells to support Erk activation in response to thapsigargin. Thapsigargin-induced Erk activation was almost entirely abrogated in Stim1-overexpressing RasGRP-deficient cells, but was completely unaffected in SOS-deficient cells overexpressing Stim1 (Fig. 5a). We thus generated Rasgrp1−/−Rasgrp3−/− DT40 cell lines stably overexpressing eYFP-Stim1 (Supplementary Fig. 4a), which exhibited a similar increase in SOCE to that observed in wild-type DT40 cells overexpressing Stim1 (Supplementary Fig. 4b). As expected after the transient transfection experiments, these cells displayed a near-complete loss of Erk activation in response to thapsigargin (Supplementary Fig. 4c). RasGrp deficiency rescued DT40 cells from BCR-induced apoptosis, even when Stim1 was overexpressed (Fig. 5b). These results demonstrate that RasGrp is required to mediate Erk activation by Ca2+ and disrupting Ca2+-dependent activation of RasGrp and Erk is sufficient to inhibit antigen receptor-induced apoptosis.
Figure 5
Figure 5
Activation of Erk downstream of Ca2+ requires RasGrp
PKC-mediated phosphorylation of RasGrp is known to be important for its activation25, 26, 36, 37. To determine whether Ca2+-dependent activation of Erk requires PKC activity, we examined the effect of two different PKC inhibitors, GF-109203X and Gö6976, on thapsigargin- or anti-BCR-induced pErk. Surprisingly, the two PKC inhibitors had opposite effects. GF-109203X potently inhibited the response to thapsigargin while having a minor effect on the anti-BCR response. Gö6976 did not inhibit the response to thapsigargin, but inhibited most of the anti-BCR-induced pErk response, with the remaining pErk being Ca2+-dependent (Fig. 5c). This result is consistent with previous studies examining the role of Gö6976 on BCR-induced pErk36, 37. Therefore, Gö6976 inhibits the DAG-dependent component of the BCR-mediated Erk response, but not the Ca2+-dependent response. In contrast, GF-109203X inhibits the Ca2+-dependent Erk response, but not the DAG-dependent response. Although both of these inhibitors are known to inhibit classical PKCs with similar potency, their ability to inhibit non-classical PKCs is different. GF-109203X, but not Gö6976, can efficiently block PKCδ activity38, suggesting that this PKC isoform plays a critical role in Ca2+ dependent Erk signaling.
Ca2+-Erk signaling requires phospho-S332 RasGRP1
The cooperation between PKC and RasGRP proteins has been well documented, but the only phosphorylation site that has thus far been identified as a target of PKCs is RasGRP1 T184, which corresponds to T133 of RasGRP3 (refs. 36, 37). Interestingly, neither of these sites fits a PKCδ consensus target sequence. Moreover, phosphorylation of these sites is blocked by Gö6976, which does not inhibit PKCδ or Ca2+-dependent Erk activation. Indeed, we found that T133 RasGRP3 was not phosphorylated in response to thapsigargin, and a T184A mutant RasGRP1 was largely functional in mediating Erk activation in response to SOCE (data not shown). Therefore, we hypothesized that PKCδ could potentially phosphorylate RasGRP on other sites and thereby induce activation of a functionally distinct Erk pathway. To test this hypothesis, we selected candidate sites on human RasGRP1 based on three criteria. One, putative sites possess a PKCδ consensus target sequence (S/TXXR/K); two, these sites should have a predictive phosphorylation score above 0.8 on the Netphos 2.0 server (http://www.cbs.dtu.dk/services/NetPhos/)39; and three, sites should be conserved across species (chicken, mouse and human) (Supplementary Fig. 5a). Five potential serine or threonine sites were identified on RasGRP1, and were individually mutated to alanine. These mutants or wild-type human RasGRP1 were transiently transfected into the Stim1-overexpressing RasGRP-deficient DT40 cells. The transfected cells were then stimulated with thapsigargin and the pErk response within the tranfected population was examined. Four of the five mutant proteins were able to support Ca2+-dependent Erk activation (Supplementary Fig. 5b). However, RasGRP1 S332A was completely deficient in activation of this pathway, resulting in comparably low pErk activation as observed in the parental RasGRP-deficient cells (Fig. 6a). The S332A mutant RasGRP1 was expressed in an amount comparable to that observed in wild-type RasGRP1 transfectants (Supplementary Fig. 6), ensuring that this effect was not due to lack of expression or decreased stability of the protein. We then examined the ability of this mutant to support DAG-mediated Erk activation.
Figure 6
Figure 6
Phosphorylation of S332 RasGRP1 is required for RasGRP1 to restore Ca2+-dependent Erk activation in RasGRP-deficient cells
Remarkably, when the cells were stimulated with anti-BCR in the presence of EGTA, the S332A mutant RasGRP1 was able to support activation of Erk, albeit less than wild-type RasGRP1 (Fig. 6b). This result demonstrates that the S332A mutation does not result in a completely inactive nucleotide exchange factor, but rather represents a crucial site that modulates the selective responsiveness of the exchange factor to Ca2+-induced signals. To further address whether S332 phosphorylation is involved in Ca2+-induced Erk activation, we generated a phosphomimetic S332D RasGrp1 mutant. The S332D mutant was fully functional and induced Erk activation in response to Ca2+ to the same extent as wild-type RasGRP1 (Fig. 6c). The same was true of the DAG-dependent BCR response, as measured by stimulation with anti-BCR in the presence of EGTA (Fig. 6d). These results demonstrate that phosphorylation of S332 is absolutely required for Ca2+-dependent, but not for the DAG-dependent BCR-induced Erk activation. Interestingly, cells expressing the phosphomimetic mutant RasGrp1 did not exhibit constitutive Erk activation in unstimulated cells, suggesting that although phosphorylation of S332 is required, it may not be sufficient to constitutively activate the pathway.
Given the robust impact of the S332A mutation on the ability of RasGRP1 to mediate Ca2+-dependent Erk activation, we performed homology modeling using the ModWeb server40 and the template mouse RasGRF1 (pdb 2IJE)41 to gain insight into the possible role this site could play in the regulation of RasGRP1 activity (Fig. 6e). Interestingly, this model predicts that S332 lies on the “flap2” region of the CDC25 domain, where a phosphorylation event could affect Ras binding and/or the positioning of the catalytic helical hairpin.
Developmental regulation of Stim1, RasGRP and PKCδ
To determine whether developmental regulation of protein expression might play a role in the selective activation of this pathway during negative selection, we sorted bone marrow B cell subsets and examined the expression of Stim1, PKCδ and RasGRP proteins. Consistent with a role for this pathway in antigen-induced apoptosis, expression of RasGRP1, RasGRP3, PKCδ and Stim1 were all increased at the bone marrow transitional stage, where negative selection occurs (Supplementary Fig. 7). This stage was also where higher amplitude and faster kinetics of thapsigargin-induced SOCE (Supplementary Fig. 8) and maximal thapsigargin-induced pErk responses occurred (Fig. 3). Expression of RasGRP1, PKCδ and Stim1 was then downregulated in mature B cells, while RasGRP3 abundance increased further in mature B cells. The pattern of PKCδ expression was consistent with previously published results examining expression of the LacZ gene that was introduced into the Prkcd locus in the Prkcd−/− mice21.
Likewise, the increase in RasGRP1 and PKCδ protein in bone marrow transitional B cells was also consistent with robust changes in mRNA abundance reported in the Immunological Genome Research Project (IMMGEN) website (http://www.immgen.org/databrowser/index.html). These results suggest that transient increases in RasGRP1, PKCδ and Stim1 could contribute to the preferential activation of the Ca2+-Erk pathway in developing B cells, and that downregulation of these proteins in mature B cells may contribute to the loss of sensitivity to antigen-induced apoptosis. By contrast, the expression pattern of RasGRP3 suggests this protein may also be involved in DAG-mediated Erk signaling in mature B cells.
Ca2+-Erk signaling in developing B cells requires PKCδ
The notion that PKCδ may be required for Ca2+-dependent Erk activation during B cell negative selection is intriguing, given the phenotype of Prkcd−/− mice21, 22. These mice display two-fold and seven-fold increases in B cell numbers in the spleen and lymph nodes, respectively. In these mice, self-reactive B cells develop, terminally differentiate, but fail to become anergized. The Prkcd−/− mice develop anti-nuclear antibodies and die prematurely at 9–12 months of age due to autoimmune disease. Previous studies on these mice have focused on defects in peripheral B cell homeostasis that contribute to the phenotype42. However, based on the developmental regulation of Ca2+-dependent Erk activation, we hypothesized that the phenotype of the Prkcd−/− mice may be at least partly due to an inability to activate the Ca2+-regulated Erk pathway during B cell negative selection. We performed competitive repopulation experiments, where Prkcd−/− and wild-type bone marrow cells were mixed at a 1:1 ratio and injected into lethally irradiated mice. As expected, the Prkcd−/− B cells out-competed the wild-type cells (Fig. 7a). Interestingly, the earliest developmental stage where this effect was observed coincided with the bone marrow stage where Ca2+-dependent Erk activation occurred and where increases in Stim1 expression enhanced negative selection, whereas it was not observed in the developmental stages prior to antigen receptor expression. This observation suggests that the competitive advantage of Prkcd−/− B cells relates to alteration of developmental stage-specific signals.
Figure 7
Figure 7
PKCδ is required for Ca2+-dependent Erk activation in developing bone marrow cells
We then hypothesized that the competitive advantage of Prkcd−/− bone marrow transitional B cells might relate to a loss of pro-apoptotic Ca2+-Erk signaling at this developmental stage. Thapsigargin-induced SOCE was comparable or slightly higher in Prkcd−/− cells than in wild-type cells (Supplementary Fig. 8). However, Ca2+-dependent Erk activation was markedly impaired in Prkcd−/− bone marrow developing B cells (Fig. 7b,c). The cell populations analyzed contain comparable numbers of newly generated B cells in both genotypes, as revealed by the rates of BrdU incorporation (Supplementary Fig. 9). Therefore, loss of Ca2+-dependent Erk signaling in transitional Prkcd−/− bone marrow B cells may increase survival of self-reactive B cells that would otherwise undergo apoptosis, thus setting the stage for the previously described autoimmune phenotype (Supplementary Fig. 10a,b). By contrast, enhancing activation of this pathway by increasing Stim1 concentrations (Fig. 4) may lead to increased activation of this pathway, leading to increased negative selection (Supplementary Fig. 10c).
PKCδ deficiency rescues Stim1-overexpressing B cells
Lastly, we sought to examine whether the Stim1-mediated sensitization of B cells to negative selection in the bone marrow (Fig. 4) depends on this SOCE-PKCδ-RasGRP-Erk pathway. We infected wild-type or Prkcd−/− HSCs with eYFP-Stim1, then mixed at a 1:1 ratio with eYFP-infected wild-type cells, and injected the mixed population into lethally irradiated recipients. The mice were analyzed 6–8 weeks post-injection, and the eYFP-Stim1:eYFP ratio was determined throughout the bone marrow developing B cell populations. As previously shown in Fig. 4, wild-type Stim1-overexpressing B cells displayed a competitive disadvantage at the immature and transitional stages in the bone marrow (Fig. 8, black bars). In contrast, Stim1-overexpressing Prkcd−/− B cells displayed a competitive advantage over wild-type cells expressing eYFP alone (Fig. 8, gray bars), indicating that PKCδ is required for Stim1 to sensitize B cells to negative selection at this developmental stage. Interestingly, the composition of the mature recirculating B cell population in these mice was highly variable (data not shown), perhaps indicative of a more complex epistatic relationship between PKCδ and Stim1 in peripheral B cell homeostasis. Nevertheless, these results further support a model where Ca2+-dependent Erk signaling, mediated by PKCδ and RasGRP proteins, sets a threshold for negative selection in the bone marrow (Supplementary Fig. 10).
Figure 8
Figure 8
PKCδ is required for Stim1-mediated sensitization of bone marrow B cells to negative selection
Our data reveal the existence of a Ca2+-dependent pro-apoptotic pathway to Erk activation, which mediates a critical checkpoint during B cell development. We therefore propose a model where Ca2+ and DAG can direct Erk to distinct functional outcomes during B cell development. Because DAG and IP3 are produced at equal molar concentrations downstream of PLCγ-mediated hydrolysis of PtdIns(4,5)P2, DAG production is inextricably linked to Ins(1,3,4)P3 -induced SOCE. However, the amplitude and duration of DAG production and SOCE largely depends on proteins that amplify or negatively regulate these second messengers. For example, higher amounts of Stim1 protein (which we observed in bone marrow transitional cells) may contribute to amplify SOCE. By contrast, lower DAG production, which have been previously reported in immature B cells10, may be the result of rapid DAG turn-over mediated by DAG kinases, DAG acyltransferases or DAG lipases, all of which metabolize DAG into different products. Data from the IMMGEN website show that mRNA abundance for some of these proteins, such as DGKδ, DGKτ, DGKη, DGLβ or DGAT2L6, change during B cell development in ways that may affect DAG metabolism. In addition, we have found that considerable changes in expression of proteins that mediate the activation of Erk pathways during development also contribute to their amplification, as demonstrated by the robust increases of RasGRP1 and PKCδ expression in transitional bone marrow B cells relative to other B cell subsets. These changes in expression are likely critical to setting the appropriate threshold of antigenic signal strength that results in negative selection.
The involvement of PKCδ in this pro-apoptotic Erk pathway is intriguing and was not expected. PKCδ has been implicated in apoptosis of multiple cell types43, 44, but the potential involvement of pro-apoptotic Ras–Erk signaling as an effector pathway downstream of PKCδ has not been explored. Therefore, our data implicating PKCδ in antigen-induced pro-apoptotic Ras–Erk signaling establish a new paradigm that could be tested in other systems where PKCδ is important to mediate apoptosis. It has been clearly demonstrated that Prkcd−/− mice display a defect in peripheral B cell homeostasis which increases the lifespan of B cells and is independent of selection events21, 42. However, our data involving PKCδ in pro-apoptotic Erk signaling during negative selection now suggest that loss of PKCδ may also result in previously unrecognized alterations to the B cell repertoire that contribute to the disease pathology of the mice. Interestingly, PKCδ has been reported to be dispensable in a transgenic model of negative selection mediated by expression of membrane-bound hen egg lysozyme (HEL) in MD4 mice, which express IgHEL-specific B cells21, implying that this may not be the only pathway mediating B cell negative selection. However, membrane-bound HEL in that model provides an exceedingly strong antigenic stimulus, in particular to a high affinity BCR transgene, which may override mechanisms that establish selection thresholds for many antigens in normal cells, thus leading to B cell deletion at the earliest bone marrow immature stage45, 46. Because the onset of PKCδ-mediated, Ca2+-dependent Erk activation occurs in IgMhiIgDint bone marrow transitional B cells, it is not surprising that the mHEL system does not reveal the role of PKCδ in negative selection.
Ras and Erk activation have been intensively studied in lymphocytes, and have mostly been thought of as DAG-dependent and Ca2+-independent. Our findings demonstrate that more than one pathway leading to Erk activation exists in B lymphocytes, and here we show that a Ca2+-dependent Erk activation pathway directs the functional outcome of the stimulus towards an apoptotic fate in developing B cells. Because RasGRP1 is prominently and exclusively expressed in B cell subsets where this pathway is active, we focused on defining the biochemical mechanisms by which Ca2+ may influence its function. We have thus identified S332 on RasGRP1 as a potential phosphorylation site that is a likely PKCδ target and which was clearly required for Ca2+-dependent Erk activation. Unexpectedly, this site is located within the CDC25 domain of RasGRP1, the domain that actually mediates the interaction with Ras and consequently the nucleotide exchange function of the protein. Because of this, a phosphorylation event that preserves nucleotide exchange function (as is the case with S332) is unlikely to trigger structural reorganization of the protein. Based on homology modeling with the CDC25 of RasGRF141, 47, we predict that this site lies in the “flap2” region of the CDC25 domain, which may have a role in positioning the catalytic helical hairpin of the exchange factor for catalysis. This residue is strikingly close to the Ras binding site and, because of the increase in negative charge associated with phosphorylation, electrostatic interactions may influence the choice of Ras isoform that interacts with RasGRP1. This interesting idea that may help explain how distinct Ras protein signaling pathways that rely on Erk achieve specificity.
The Ras–Erk pathway is remarkably promiscuous in terms of potential substrates, and it has been suggested that specificity is achieved through compartmentalization mediated by scaffolds that constrain active Erk to signaling complexes where they can be activated by appropriate stimuli and simultaneously gain access to appropriate substrates4850. As mentioned above, phosphorylation of S332 on RasGRP1 could potentially contribute to such specificity. However, although it is clear that phosphorylation of S332 RasGRP1 is essential for SOCE to induce activation of this Erk pathway, the results with the phosphomimetic mutant suggest that this event is also not sufficient to activate it, and that other Ca2+ -dependent events may be required. Because PKCδ is not thought to bind Ca2+ directly, it is possible that Ca2+ binding to RasGRP via the EF hands contributes to promote RasGRP activity, possibly by facilitating the interaction with PKCδ. Moreover, at this point we cannot exclude the possibility that other Ca2+-responsive proteins may play a role within this signaling complex, perhaps by further modifying PKCδ and/or RasGRP and potentiating their activity. Concentration gradients of DAG and Ca2+ are also known to affect localization of signaling proteins, and may contribute to directing distinct Erk pathways to unique compartments within the cell. Interestingly, recent results in thymocytes have implicated differential localization of MAPK signals in setting the thresholds of positive and negative selection51. These findings, combined with our data, suggest that Ca2+ and DAG may control selection by directing the assembly and localization of different MAPK signaling complexes.
Cell culture
[var phi]NX and 3T3 cells were maintained in DMEM (CellGro) supplemented with 10% FBS, Penicillin, Streptomycin, and L-Glutamine (complete media). DT40 cells were maintained in complete RPMI (Gibco) with additional 1% chicken serum and β-mercaptoethanol (Gibco). Rasgrp1−/−Rasgrp3−/− and Sos1−/−Sos2−/− DT40 cells were previously described32.
Mice
Prkcd−/− mice were previously described21. C57BL/6 and BoyJ mice were purchased from Jackson Laboratory. Mouse experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at UCSF.
Antibodies, reagents and inhibitors
Antibodies to murine IgD (11–26), IgM (II/41), B220 (RA3-6B2), CD45.1 (A20), CD45.2 (104), CD43 (S7), CD21 (7G6), CD23 (B3B4), CD93 (AA4.1) conjugated to FITC, PE, PerCP-Cy5.5, PE-Cy7, Pacific Blue, allophycocyanin, or Alexa Fluor 647 were obtained from eBioscience, Biolegend or BD Biosciences. Annexin V conjugated to PE or Pacific Blue were from BD Biosciences and Biolegend. DAPI was from Roche. FITC-conjugated F(ab) monomeric fragment and goat anti-rabbit IgG Abs conjugated to allophycocyanin were obtained from Jackson ImmunoResearch Laboratories. CD16 antibody conjugated to PE or allophycocyanin was obtained from Caltag Laboratories. Phospho-Erk (#197G2), total Erk (#9102), RasGRP3 (C33A3) and PKCδ (#2058) antibodies were obtained from Cell Signaling, RasGRP1 (m199) antibody from Santa Cruz and Stim1 (#610954) antibody from BD. Thapsigargin, Gö6976 and GF-109203X were obtained from Calbiochem. IL-3, IL-6 and stem cell factor were obtained from Peprotech. Lipofectamine 2000 was from Invitrogen. BrdU labeling was performed per manufacturer’s instructions using the BrdU labeling kit from BD.
Plasmids, retroviruses, transfections and infections
The pDS SP-YFP-Stim1and pEF- Flag-hDGKζ plasmids were previously described1328. For DT40 transfections, cells were washed and resuspended at 6.6 × 107 cells/ml in serum-free RPMI. The cells were electroporated at 300V for 10 msec using a square-wave electroporator (BTX ECM 800), rested for 15 min, and plated in complete DT40 media without antibiotics.
Retroviral eYFP and eYFP-Stim1 constructs were generated by subcloning these genes into an MSCV-IThy1.1 vector by blunt-end ligation. A peYFP-N1 plasmid (Clontech) was digested with NheI and Not1, the eYFP-Stim1 plasmid with NheI and BglII, and the vector with NotI. All digested DNA fragments were blunted and ligated using a blunt-end ligation kit (Takara). Retroviruses were generated by Lipofectamine 2000 cotransfection (carried out per manufacturer’s instructions) of these constructs with pCL-Eco into [var phi]NX-Eco cells. Supernatants were collected 24 and 48 h post-transfections. 3T3 cells were infected with the viral supernatants and viral titers were determined based on percent eYFP-expressing cells by FACS. Only supernatants with titers higher than 106 particles/ml (assuming every virus infects a cell and a cell does not divide following infection) were used for infections of primary bone marrow cells. For infections, MACS-purified hematopoietic stem cells were incubated overnight in complete DMEM supplemented with 15% FCS, 20 ng/ml IL-3, 10 ng/ml IL-6 and 100 ng/ml SCF. On day 2, the cells were resuspended in viral supernatant supplemented with 8 μg/ml polybrene, 15% FCS, 20 ng/ml IL-3, 10 ng/ml IL-6 and 100 ng/ml SCF, and plated on 6-well plates. Cells were centrifuged for 2 h at 30 °C and incubated overnight at 37 °C. The infection was repeated on day 3, and injections were carried out on day 4 (see bone marrow reconstitutions section).
Immunoprecipitation, immunoblotting and mass spectrometry analysis
DT40 cells were lysed in 1% NP40 buffer supplemented with protease and phosphatase inhibitors at 107 cells/ml. Sorted bone marrow cells were lysed at 5 × 106 cells/ml. Immunoblotting and immunoprecipitations were performed essentially as described before25. For mass spectrometry analysis, 4G10 immunoprecipitates were resolved by SDS-PAGE, stained with colloidal blue (Invitrogen), and the band of interest was excised and digested with trypsin. Tryptic digests were submitted to the Biomolecular Resource Center Mass Spectrometry Facility at UCSF for nano-electrospray LC/MS/MS and peptide mass fingerprint analyses.
Intracellular Ca2+ measurements
Cells were loaded with Indo-1 (Molecular Probes) per manufacturer’s instructions. Ca2+-free and Ca2+-bound emissions were measured during stimulation of the cells using a fluorimeter (Hitachi F-4500 or Molecular Devices Flexstation3). Primary cells were analyzed by multicolor flow cytometry as previously described9.
Intracellular pErk staining
Primary bone marrow cells were harvested on pre-warmed serum-free DMEM supplemented with HEPES pH 7.2, non-essential aminoacids, sodium pyruvate, β-Mercaptoethanol, penicillin, streptomycin and L-Glutamine. Cells were rested at 37 °C for 1 h in media containing a 1:5000 dilution of non-stimulatory FITC- labeled F(ab) monomeric fragment, then stimulated with thapsigargin for the indicated times, fixed with pre-warmed cytofix (BD) for 15 min, washed twice with flow cytometry buffer, and permeabilized in ice-cold methanol for 45 min on ice. Cells were then washed three times, incubated for 45 minutes in flow cytometry buffer containing pErk (Cell Signaling) antibody with 4% mouse serum, washed twice and stained with an anti-rabbit secondary antibody, along with antibodies against B220 and IgD. The cells were then analyzed by flow cytometry (as detailed in Supplementary methods). The same protocol was followed for DT40 cells, except stimulation was performed in serum- free RPMI supplemented with β-mercaptoethanol, and the staining was only for pErk (except for transiently transfected cells, which were costained for CD16).
Bone marrow reconstitutions
Bone marrow cells from donor mice as indicated for each experiment were harvested, stem cells were purified using a MACS stem cell purification kit (Miltenyi Biotech) and cultured overnight in complete media containing IL-3, IL-6 and SCF. The cells were then infected with retroviruses carrying eYFP or eYFP-Stim1. The cells were counted, mixed at a 1:1 ratio, mixed with a 1:1 mixture of uninfected carrier bone marrow of the same genotype and injected into irradiated CD45.2+/+ host recipients. Bone marrow, spleen and lymph nodes from host recipients were harvested 8–10 weeks post-injection and analyzed by flow cytometry.
Flow Cytometry
Single cell suspensions were prepared from bone marrow, lymph nodes (LN) and spleens. Fc receptors were blocked with rat anti-CD16/32 (clone 2.4G2; BD Biosciences). 1–3 × 106 cells were stained with the indicated Abs and analyzed on a FACSCalibur (BD Biosciences), CyAN ADP (Beckman Coulter), Gallios (Beckman Coulter) or LSRII (BD Biosciences) flow cytometry system. Forward and side scatter exclusion was generally used to identify live cells. For analysis of bone marrow chimeras, costaining with DAPI was used to exclude dying cells as well. Data analysis was performed using FlowJo (version 8.8.4) software (Tree Star). Cell sorting was performed using a MoFlo system.
Statistical analysis
Error bars were calculated as standard error of the mean with n ranging between 3 and 11 as indicated in each figure legend. P values for comparisons across B cell subsets were calculated using a paired T test, where values for each individual mouse were paired. P values for comparisons across different mice (of different genotype) were calculated using unpaired T test.
Supplementary Material
supp info
Acknowledgments
We would like to acknowledge the Sandler-Moore Mass Spectrometry Core Facility at UCSF for their assistance in protein identification; this core is funded by the Sandler Family Foundation, the Gordon and Betty Moore Foundation and the Cancer Center Support Grant NIH/NCI P30 CA82103. We acknowledge the assistance of the Flow Cytometry Core Facility at the Department of Pathology and Diabetes Center, UCSF. We thank Gary Koretzky for providing the pEF-Flag-hDGKζ plasmid. We thank A. Roque for assistance with animal husbandry, H. Phee and M. Hermiston for critically reading the manuscript and providing helpful suggestions, B. Au-Yeung and H. Wang for help with tail-vein injections and members of the Weiss laboratory for helpful discussions. This work was supported by the Howard Hughes Medical Institute and the Sidney Kimmel Foundation (JPR).
Footnotes
Author Contributions
A.L. designed and performed experiments, analyzed the data and wrote the manuscript. P.D. collaborated with A.L. on determining expression levels of various proteins on sorted bone marrow B cell populations and in harvesting reconstituted mice. T.F. performed homology modeling on RasGRP1. J.L. and T.K. provided reagents. M.L. generated the Prkcd−/− mice. J.R. designed experiments and provided reagents. A.W. designed experiments, supervised the research, revised the manuscript and provided support.
1. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med. 1993;177:999–1008. [PMC free article] [PubMed]
2. Goodnow CC, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988;334:676–682. [PubMed]
3. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 1989;337:562–566. [PubMed]
4. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med. 1993;177:1009–1020. [PMC free article] [PubMed]
5. Wardemann H, et al. Predominant autoantibody production by early human B cell precursors. Science (New York, N Y. 2003;301:1374–1377. [PubMed]
6. Hertz M, Nemazee D. BCR ligation induces receptor editing in IgM+IgD- bone marrow B cells in vitro. Immunity. 1997;6:429–436. [PubMed]
7. Melamed D, Benschop RJ, Cambier JC, Nemazee D. Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. Cell. 1998;92:173–182. [PubMed]
8. Benschop RJ, Brandl E, Chan AC, Cambier JC. Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation. J Immunol. 2001;167:4172–4179. [PubMed]
9. Gross AJ, Lyandres JR, Panigrahi AK, Prak ET, DeFranco AL. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J Immunol. 2009;182:5382–5392. [PMC free article] [PubMed]
10. Hoek KL, et al. Transitional B cell fate is associated with developmental stage-specific regulation of diacylglycerol and calcium signaling upon B cell receptor engagement. J Immunol. 2006;177:5405–5413. [PubMed]
11. King LB, Norvell A, Monroe JG. Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells. J Immunol. 1999;162:2655–2662. [PubMed]
12. Parekh AB, Putney JW., Jr Store-operated calcium channels. Physiol Rev. 2005;85:757–810. [PubMed]
13. Liou J, et al. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol. 2005;15:1235–1241. [PMC free article] [PubMed]
14. Roos J, et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol. 2005;169:435–445. [PMC free article] [PubMed]
15. Zhang SL, et al. STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature. 2005;437:902–905. [PMC free article] [PubMed]
16. Liou J, Fivaz M, Inoue T, Meyer T. Live-cell imaging reveals sequential oligomerization and local plasma membrane targeting of stromal interaction molecule 1 after Ca2+ store depletion. Proc Natl Acad Sci USA. 2007;104:9301–9306. [PubMed]
17. Luik RM, Wu MM, Buchanan J, Lewis RS. The elementary unit of store-operated Ca2+ entry: local activation of CRAC channels by STIM1 at ER-plasma membrane junctions. J Cell Biol. 2006;174:815–825. [PMC free article] [PubMed]
18. Park CY, et al. STIM1 clusters and activates CRAC channels via direct binding of a cytosolic domain to Orai1. Cell. 2009;136:876–890. [PMC free article] [PubMed]
19. Spassova MA, et al. STIM1 has a plasma membrane role in the activation of store-operated Ca(2+) channels. Proc Natl Acad Sci USA. 2006;103:4040–4045. [PubMed]
20. Wu MM, Buchanan J, Luik RM, Lewis RS. Ca2+ store depletion causes STIM1 to accumulate in ER regions closely associated with the plasma membrane. J Cell Biol. 2006;174:803–813. [PMC free article] [PubMed]
21. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature. 2002;416:860–865. [PubMed]
22. Miyamoto A, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature. 2002;416:865–869. [PubMed]
23. Dower NA, et al. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol. 2000;1:317–321. [PubMed]
24. Roose J, Weiss A. T cells: getting a GRP on Ras. Nat Immunol. 2000;1:275–276. [PubMed]
25. Roose JP, Mollenauer M, Gupta VA, Stone J, Weiss A. A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells. Mol Cell Biol. 2005;25:4426–4441. [PMC free article] [PubMed]
26. Teixeira C, Stang SL, Zheng Y, Beswick NS, Stone JC. Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood. 2003;102:1414–1420. [PubMed]
27. Downward J, Graves JD, Warne PH, Rayter S, Cantrell DA. Stimulation of p21ras upon T-cell activation. Nature. 1990;346:719–723. [PubMed]
28. Zhong XP, et al. Enhanced T cell responses due to diacylglycerol kinase zeta deficiency. Nat Immunol. 2003;4:882–890. [PubMed]
29. Das J, et al. Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell. 2009;136:337–351. [PMC free article] [PubMed]
30. Ebinu JO, et al. RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs. Science (New York, N Y. 1998;280:1082–1086. [PubMed]
31. Ebinu JO, et al. RasGRP links T-cell receptor signaling to Ras. Blood. 2000;95:3199–3203. [PubMed]
32. Oh-hora M, Johmura S, Hashimoto A, Hikida M, Kurosaki T. Requirement for Ras guanine nucleotide releasing protein 3 in coupling phospholipase C-gamma2 to Ras in B cell receptor signaling. J Exp Med. 2003;198:1841–1851. [PMC free article] [PubMed]
33. Roose JP, Mollenauer M, Ho M, Kurosaki T, Weiss A. Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol Cell Biol. 2007;27:2732–2745. [PMC free article] [PubMed]
34. Guilbault B, Kay RJ. RasGRP1 sensitizes an immature B cell line to antigen receptor-induced apoptosis. J Biol Chem. 2004;279:19523–19530. [PubMed]
35. Stang SL, et al. A proapoptotic signaling pathway involving RasGRP, Erk, and Bim in B cells. Exp Hematol. 2009;37:122–134. [PMC free article] [PubMed]
36. Aiba Y, et al. Activation of RasGRP3 by phosphorylation of Thr-133 is required for B cell receptor-mediated Ras activation. Proc Natl Acad Sci USA. 2004;101:16612–16617. [PubMed]
37. Zheng Y, et al. Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood. 2005;105:3648–3654. [PubMed]
38. Martiny-Baron G, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem. 1993;268:9194–9197. [PubMed]
39. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999;294:1351–1362. [PubMed]
40. Eswar N, et al. Tools for comparative protein structure modeling and analysis. Nucleic acids res. 2003;31:3375–3380. [PMC free article] [PubMed]
41. Freedman TS, et al. A Ras-induced conformational switch in the Ras activator Son of sevenless. Proc Natl Acad Sci USA. 2006;103:16692–16697. [PubMed]
42. Mecklenbrauker I, Kalled SL, Leitges M, Mackay F, Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature. 2004;431:456–461. [PubMed]
43. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J. 2004;384:449–459. [PubMed]
44. Yoshida K. PKCdelta signaling: mechanisms of DNA damage response and apoptosis. Cell Signal. 2007;19:892–901. [PubMed]
45. Hartley SB, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell. 1993;72:325–335. [PubMed]
46. Hartley SB, et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991;353:765–769. [PubMed]
47. Freedman TS, et al. Differences in flexibility underlie functional differences in the Ras activators son of sevenless and Ras guanine nucleotide releasing factor 1. Structure. 2009;17:41–53. [PMC free article] [PubMed]
48. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 2005;6:827–837. [PubMed]
49. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci. 2006;31:268–275. [PubMed]
50. Philips MR. Compartmentalized signalling of Ras. Biochem Soc Trans. 2005;33:657–661. [PubMed]
51. Daniels MA, et al. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature. 2006;444:724–729. [PubMed]